Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam Dose and Safety in Children With Congenital Heart Disease
ChiCTR2300076458Phase 4Not yet recruiting
- Sponsor
- Fuwai Central China Cardiovascular Hospital
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of remimazolam in Cardiovascular Malformation (CVM) (3 arms), sponsored by Fuwai Central China Cardiovascular Hospital. Primary endpoints: ED50 and ED95. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
Cardiovascular Malformation (CVM)
Beyond the preview
Go deeper on ChiCTR2300076458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076458.